Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

Pharmacogenetics of Neoadjuvant MAP Chemotherapy in Localized Osteosarcoma: A Study Based on Data from the GEIS-33 Protocol

<b>Background:</b> Osteosarcoma is a rare disease, but it is the most frequent malignant bone tumor. Primary treatment consists of preoperative MAP (methotrexate (MTX), doxorubicin and cisplatin) chemotherapy followed by surgery and adjuvant chemotherapy. Pathological response to preoper...

Full description

Saved in:
Bibliographic Details
Main Authors: Juliana Salazar, María J. Arranz, Javier Martin-Broto, Francisco Bautista, Jerónimo Martínez-García, Javier Martínez-Trufero, Yolanda Vidal-Insua, Aizpea Echebarria-Barona, Roberto Díaz-Beveridge, Claudia Valverde, Pablo Luna, María A. Vaz-Salgado, Pilar Blay, Rosa Álvarez, Ana Sebio
Format: Article
Language:English
Published: MDPI AG 2024-12-01
Series:Pharmaceutics
Subjects:
osteosarcoma
neoadjuvant chemotherapy
pharmacogenomics
personalized medicine
Online Access:https://www.mdpi.com/1999-4923/16/12/1585
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1999-4923/16/12/1585

Similar Items